Synergy Empire Ltd: M&A transaction — Synergy Empire acquires Meluha Therapeutics for $2.3M in preferred stock; shifts to stem cell medicine

Synergy Empire Ltd

Acquired 100% of Meluha Therapeutics on March 28, 2025, for 10M Series A preferred shares valued at $2.3M.
Company pivots from F&B consultancy to biopharmaceutical manufacturing of stem cell therapies.
Meluha directors Ramesh A/L Saravanamuthu and Abdul Jalil bin Jidon received 3.36M and 3.19M preferred shares respectively.
No financial details of Meluha (revenue/profit) disclosed in the filing.

item 1.01 item 2.01 item 3.02 item 5.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Synergy Empire Ltd completed an acquisition involving Meluha Therapeutics Berhad for 10,000,000 shares of Series A preferred stock valued at $0.23 per share for an aggregate value of $2,300,000 (closed 2025-03-28).

Action: acquisition
Counterparty: Meluha Therapeutics Berhad
Consideration: 10,000,000 shares of Series A preferred stock valued at $0.23 per share for an aggregate value of $2,300,000
Closing: 2025-03-28

Exact text from the filing

Meluha Therapeutics Berhad (“Meluha”), a limited company incorporated under the laws of Malaysia, and the shareholders of Meluha. Pursuant to the Agreement, we agreed to purchase 10,000,000 shares of Meluha (the “Meluha Shares”), representing all of the issued and outstanding shares of common stock of Meluha, which were held by all the shareholders of Meluha. As a

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001641172-25-002536

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.